FDA Cybersecurity Enforcement in Medical Devices: What Manufacturers Need to Know in 2025

FDA Cybersecurity Enforcement Is No Longer a Future Risk — It Is Here Now

For years, cybersecurity was treated as a checkbox in medical device submissions — an afterthought appended to a 510(k) or PMA rather than a core design discipline. That era is over. FDA has made cybersecurity one of its highest enforcement priorities, and the agency now has explicit statutory authority to refuse acceptance of premarket submissions that fail to meet cybersecurity requirements. If your organization has not fundamentally updated its approach, you are already behind.

This post breaks down the current enforcement landscape, identifies where manufacturers are getting caught, and outlines the practical steps your quality and regulatory teams need to take now.

The Legal Framework: Section 524B and What It Actually Requires

The Consolidated Appropriations Act of 2023 amended the Federal Food, Drug, and Cosmetic Act by adding Section 524B, which took effect on March 29, 2023. This provision requires sponsors of cyber devices — defined as any device that includes software, connects to the internet, or contains a technological characteristic that could be vulnerable to cybersecurity threats — to submit specific cybersecurity documentation as part of every premarket submission.

Under Section 524B, manufacturers must provide:

• A plan to monitor, identify, and address post-market cybersecurity vulnerabilities and exploits
• Procedures and processes to provide reasonable assurance that the device and related systems are cybersecure
• A software bill of materials (SBOM), including commercial, open-source, and off-the-shelf software components
• A plan for coordinated vulnerability disclosure

FDA is not treating this as a soft guidance recommendation. Failure to include compliant cybersecurity documentation in a submission triggers Refuse to Accept (RTA) under 21 CFR Part 807.87 and the agency's RTA checklist. We are seeing this enforced consistently across 510(k), De Novo, and PMA pathways.

What FDA's 2023 Cybersecurity Guidance Actually Expects

FDA's final guidance, Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions (September 2023), replaced the 2022 draft and significantly raised the technical bar. The guidance operationalizes Section 524B and introduces a structured framework with two tiers of cybersecurity risk, the Secure Product Development Framework (SPDF), and explicit expectations for threat modeling documentation.

Key areas where submissions are failing include:

• Insufficient threat modeling: FDA expects documented STRIDE or equivalent methodology, not a general narrative statement about cybersecurity controls
• Incomplete SBOMs: Submitting a partial list of software components or omitting transitive dependencies is a common deficiency that generates Additional Information (AI) requests
• Weak post-market plans: Vague language about monitoring vulnerabilities does not satisfy the requirement for a structured, documented vulnerability management process
• No coordinated vulnerability disclosure policy: Many small manufacturers still do not have a published CVD policy, which is now a submission requirement

These are not hypothetical failure modes — they represent the actual deficiency patterns we are seeing in FDA responses to submissions across multiple device categories.

Post-Market Enforcement and the Quality System Connection

Cybersecurity enforcement does not end at clearance or approval. FDA has signaled in multiple public forums and in its post-market cybersecurity guidance (December 2016, still applicable) that manufacturers have ongoing obligations under 21 CFR Part 820 to address cybersecurity as part of the design control and risk management processes.

During inspections, FDA investigators are increasingly probing cybersecurity-related procedures. Warning Letters and 483 observations have cited failures in software change control, inadequate risk analysis under 21 CFR 820.30(g), and lack of documented post-market surveillance for software vulnerabilities. For manufacturers certified to ISO 13485:2016, this maps directly to Clause 7.3 and Clause 8.2.1 — but ISO certification alone does not satisfy FDA's expectations without cybersecurity-specific procedural documentation.

What Startups and Small Manufacturers Must Do Now

Regulatory teams at startups and small-to-mid-size manufacturers face a particular challenge: FDA's expectations were written for organizations with dedicated cybersecurity engineering resources, but enforcement applies regardless of company size. Here is where to focus:

• Conduct a gap assessment against the 2023 guidance before your next submission — not during review
• Build cybersecurity into design controls from the beginning of your development cycle, with documented threat modeling and risk assessments under ISO 14971
• Generate and maintain a complete SBOM using automated tooling where possible, and establish a process to update it through the product lifecycle
• Draft and publish a coordinated vulnerability disclosure policy — this is a non-negotiable submission artifact
• Align your post-market surveillance procedures to include structured monitoring of the National Vulnerability Database (NVD) and component-specific advisories

The Cost of Getting This Wrong

An RTA determination resets your submission clock entirely. An AI request mid-review can add three to six months to your timeline. For a startup burning cash toward a market launch, a preventable cybersecurity deficiency is not just a regulatory problem — it is a business risk. For established manufacturers, a 483 observation tied to cybersecurity gaps can trigger heightened scrutiny across your entire quality system.

FDA has made clear that it views cybersecurity as a patient safety issue, not an IT issue. Enforcement will continue to intensify as connected devices proliferate and threat actors increasingly target healthcare infrastructure.

Work With a Regulatory Partner Who Understands Both Sides

At ADB Consulting & CRO Inc., we help medical device companies build submission-ready cybersecurity documentation, prepare compliant SBOMs, develop post-market vulnerability management SOPs, and respond to FDA deficiencies related to cybersecurity. Whether you are preparing your first 510(k) for a connected device or responding to a 483 observation, we bring the regulatory and technical depth to get you across the finish line.

Book a free discovery call with Andre Butler today at adbccro.com and find out exactly where your cybersecurity documentation stands — before FDA does.